Despite a significant downregulation of the OPG levels in the EPO-treated mice, cKD was not associated with a differential response of this mediator to pharmacological doses of EPO (ΔΔCT 0.114[95% CI(0.083-0.146)] vs 0.067[95% CI(0.051-0.083)] and 0.09[95% CI(0.074-0.106)] vs 0.047[95% CI(0.028-0.066)] in the diluent vs EPO-treated control and cKD mice, respectively, Figure 5G). The gene discussed is TNFRSF11B; the disease is chronic kidney disease.